Plain-English translation of NCT05779215 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
LOMEVO is a long-term study that follows 50,000 stroke patients across about 30 hospitals in China. Researchers are collecting real-world information about how doctors treat acute ischemic strokes caused by large or medium-sized blood clots in the brain — including all the different treatment approaches used in everyday clinical practice.
Doctors need to better understand what treatments work best for major stroke blood clots and how patients recover with different approaches. By gathering information from thousands of real patients over 10 years, researchers can identify patterns that help improve care and outcomes for future stroke patients.
You likely qualify if…
You likely don't qualify if…
You would be enrolled in a registry that tracks your stroke treatment and recovery over 10 years. Researchers collect information about the treatments you receive (whether that's clot-removal procedures, medications, or other standard care) and monitor your health outcomes. You don't necessarily receive any new or experimental treatment — instead, doctors document your actual clinical care as it happens.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
China
Enrollment target
~50,000 participants
Started
April 2023
Primary completion
April 2032
Last updated on clinicaltrials.gov in May 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Junwei Hao, MD; PhD
Xuanwu Hospital, Beijing
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.